Search FHI 360

Start a New Search

Search within these results

ChinaAsia Pacific Regional Office

Search

16 Results Found

• Published research

  Development and application of a multidrug-resistant tuberculosis case management system—Yunnan province, China, 2017–2020
• Project

  Strengthening Communities and Accelerating Local Engagement (SCALE)

  In western China, FHI 360 is carrying out SCALE, a project that works to strengthen ethnic minorities’ health literacy and increase the availability of culturally appropriate health services.
• Published research

  Application of the global diet quality score in Chinese adults to evaluate the double burden of nutrient inadequacy and metabolic syndrome
• Published research

  Practical experiences of delivering multidrug-resistant tuberculosis comprehensive supportive care services in China
• Published research

  Advice to use infant formula and free samples are common in both urban and rural areas in China: A cross-sectional survey
• Published research

  The China tuberculosis clinical trials consortium network: A model for international TB clinical trials capacity building
• Published research

  Breastfeeding practices and associated factors at the individual, family, health facility and environmental levels in China
• Feature

  FHI 360 delivers uninterrupted tuberculosis care during the COVID-19 pandemic

  CAP-TB’s emergency response ensures uninterrupted treatment access for multidrug-resistant tuberculosis patients in China during the COVID-19 pandemic.
• Published research

  Social, economic, and political events affect gender equity in China, Nepal, and Nicaragua: A matched, interrupted time-series study
• Published research

  Cohort study to evaluate efficacy, safety and acceptability of a two-rod contraceptive implant during third, fourth and fifth year of product use in China

  This supportive study evaluating the contraceptive efficacy of Sino-implant (II) in women shows the product to be highly effective over five years. The World Health Organization prequalified Sino-implant (II), now marketed globally as Levoplant, as a three-year contraceptive method in June 2017, resulting in the distribution of more than one million units in the following year.

• Load more